{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:25:22Z","timestamp":1790612722283,"version":"4.1.0"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0727-5","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T23:04:51Z","timestamp":1568243091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8997-2161","authenticated-orcid":false,"given":"N.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Househ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Shiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Soudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"727_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"727_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1600-065X.2009.00769.x","volume":"229","author":"RI Nurieva","year":"2009","unstructured":"Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev. 2009;229(1):88\u2013100.","journal-title":"Immunol Rev"},{"issue":"1","key":"727_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-065X.2009.00784.x","volume":"229","author":"AH Sharpe","year":"2009","unstructured":"Sharpe AH. Mechanisms of costimulation. Immunol Rev. 2009;229(1):5\u201311.","journal-title":"Immunol Rev"},{"issue":"3","key":"727_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","volume":"8","author":"AH Sharpe","year":"2007","unstructured":"Sharpe AH, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239\u201345.","journal-title":"Nat Immunol"},{"issue":"9","key":"727_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11912-018-0718-6","volume":"20","author":"DJ Palmieri","year":"2018","unstructured":"Palmieri DJ, Carlino MS. Immune checkpoint inhibitor toxicity. Curr Oncol Rep. 2018;20(9):72.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"727_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12254-018-0416-y","volume":"11","author":"JD Rudzki","year":"2018","unstructured":"Rudzki JD. Management of adverse events related to checkpoint inhibition therapy. Memo. 2018;11(2):132\u20137.","journal-title":"Memo"},{"key":"727_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1\u20138.","journal-title":"Eur J Cancer"},{"issue":"21","key":"727_CR8","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691\u20137.","journal-title":"J Clin Oncol"},{"issue":"11","key":"727_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.jtho.2017.08.007","volume":"12","author":"S Feng","year":"2017","unstructured":"Feng S, et al. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol. 2017;12(11):1626\u201335.","journal-title":"J Thorac Oncol"},{"key":"727_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342.","journal-title":"Immunol Rev"},{"key":"727_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"727_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"37","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin Ther. 2015;37(4):764\u201382.","journal-title":"Clin Ther"},{"issue":"1","key":"727_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, et al. Association of Vitiligo with Tumor Response in patients with metastatic melanoma treated with Pembrolizumab. JAMA Dermatol. 2016;152(1):45\u201351.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"727_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/bjc.2016.358","volume":"115","author":"J Belliere","year":"2016","unstructured":"Belliere J, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115(12):1457\u201361.","journal-title":"Br J Cancer"},{"key":"727_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","volume":"5","author":"J Escandon","year":"2017","unstructured":"Escandon J, et al. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother Cancer. 2017;5:3.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"727_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.pathol.2017.07.010","volume":"49","author":"K Aivazian","year":"2017","unstructured":"Aivazian K, et al. Histopathology of pembrolizumab-induced hepatitis: a case report. Pathology. 2017;49(7):789\u201392.","journal-title":"Pathology"},{"issue":"8","key":"727_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"Williams TJ, et al. Association of Autoimmune Encephalitis with Combined Immune Checkpoint Inhibitor Treatment for metastatic Cancer. JAMA Neurol. 2016;73(8):928\u201333.","journal-title":"JAMA Neurol"},{"issue":"4","key":"727_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.tcam.2012.09.003","volume":"27","author":"PJ Bergman","year":"2012","unstructured":"Bergman PJ. Paraneoplastic hypercalcemia. Top Companion Anim Med. 2012;27(4):156\u20138.","journal-title":"Top Companion Anim Med"},{"issue":"3","key":"727_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1053\/j.seminoncol.2016.02.031","volume":"43","author":"R Vyas","year":"2016","unstructured":"Vyas R, Selph J, Gerstenblith MR. Cutaneous manifestations associated with melanoma. Semin Oncol. 2016;43(3):384\u20139.","journal-title":"Semin Oncol"},{"issue":"1","key":"727_CR20","first-page":"63","volume":"10","author":"AI Liakou","year":"2012","unstructured":"Liakou AI, Trebing D, Zouboulis CC. Paraneoplastic dermatomyositis associated with metastatic melanoma. J Dtsch Dermatol Ges. 2012;10(1):63\u20134.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"Suppl 1","key":"727_CR21","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1097\/ICB.0000000000000660","volume":"12","author":"M Rahimi","year":"2018","unstructured":"Rahimi M, Navajas EV, Sarraf D. Paraneoplastic Vitelliform maculopathy associated with metastatic melanoma. Retin Cases Brief Rep. 2018;12(Suppl 1):S102\u20134.","journal-title":"Retin Cases Brief Rep"},{"issue":"10","key":"727_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.17219\/acem\/70044","volume":"27","author":"ZA Bogucki","year":"2018","unstructured":"Bogucki ZA, Kownacka M. Immunopathogenesis of ophthalmological paraneoplastic syndromes: recent findings. Adv Clin Exp Med. 2018;27(10):1441\u20135.","journal-title":"Adv Clin Exp Med"},{"issue":"7","key":"727_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773\u201381.","journal-title":"J Clin Oncol"},{"issue":"14","key":"727_CR24","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22 Pt 1","key":"727_CR25","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681\u20138.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"727_CR26","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043\u201353.","journal-title":"J Clin Oncol"},{"issue":"S11","key":"727_CR27","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.30444","volume":"123","author":"EH Byrne","year":"2017","unstructured":"Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123(S11):2143\u201353.","journal-title":"Cancer"},{"key":"727_CR28","unstructured":"D'Mello S, A., et al., Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival. Front Oncol, 2014. 3: p. 333."},{"key":"727_CR29","doi-asserted-by":"crossref","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.","journal-title":"Ther Adv Neurol Disord"},{"key":"727_CR30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3389\/fimmu.2017.00442","volume":"8","author":"MP Platt","year":"2017","unstructured":"Platt MP, Agalliu D, Cutforth T. Hello from the other side: how autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis. Front Immunol. 2017;8:442.","journal-title":"Front Immunol"},{"issue":"33","key":"727_CR31","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","volume":"31","author":"NE Thomas","year":"2013","unstructured":"Thomas NE, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31(33):4252\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"727_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12032-018-1080-0","volume":"35","author":"A Uryvaev","year":"2018","unstructured":"Uryvaev A, et al. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol. 2018;35(3):25.","journal-title":"Med Oncol"},{"issue":"1","key":"727_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","volume":"67","author":"T Balatoni","year":"2018","unstructured":"Balatoni T, et al. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunol Immunother. 2018;67(1):141\u201351.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"727_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-017-2061-4","volume":"67","author":"S Diem","year":"2018","unstructured":"Diem S, et al. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother. 2018;67(1):39\u201345.","journal-title":"Cancer Immunol Immunother"},{"key":"727_CR35","doi-asserted-by":"crossref","unstructured":"Hu-Lieskovan, S., et al., Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med, 2015. 7(279): p. 279ra241.","DOI":"10.1126\/scitranslmed.aaa4691"},{"issue":"7","key":"727_CR36","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, et al. The BRAF and MEK inhibitors Dabrafenib and Trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21(7):1639\u201351.","journal-title":"Clin Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0727-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0727-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0727-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:16Z","timestamp":1601055916000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0727-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0727-5","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient and next of kin have signed consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}